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5 
Introduction
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is 
publishing this series of profiles with the aim of describing some of the main 
characteristics of national drug policies in Europe and beyond. In contrast to other 
approaches, we do not attempt to assess these policies, but instead to outline their 
development and main features. Our objective is to help readers — from researchers 
to policymakers — gain a better understanding of the way in which countries control 
drugs and respond to drug-related security, social and health problems.
National drug policies are the result of the interaction of multiple factors, such 
as political and administrative structures, the role and influence of stakeholders, 
financial resources, the drug situation, other public policies (e.g. health, security) and 
international agreements. There is no model for how to combine these factors and 
assess their respective weight and interrelations. However, this should not prevent 
analysts from exploring the significant changes in these factors that may have shaped 
drug policy in the short and long term. This series uses a historical perspective to 
identify such drug policy changes. While some of these changes may have occurred 
in parallel in many countries because they were facing the same issues (e.g. the adoption 
of new UN conventions, HIV/AIDS epidemics, diffusion of new drugs), this series of 
policy profiles will also show that each country has its specific drug policy timeline. 
This profile, the second in the series, describes the development of drug policy in Ireland. 
The evolution of illicit drug policy in Ireland has followed an interesting course, which 
bears similarities and differences with that experienced by other European countries. 
Below, we explore the national strategies, the legal context within which they operate, 
and the public funds spent, or committed, to implement them. The profile also describes 
the political bodies and mechanisms set up to coordinate the response to the multi-faceted 
problem of drug use. The profile puts this information in context by outlining the size, 
wealth and economic situation of the country as a whole, as well as the historical deve-
lopment of the current policy. One note of caution for the reader is that the availability of 
information and analysis is much greater in the area of demand reduction, as with most 
national and international drug policy studies, than in the area of supply reduction.
What is a drug policy?
The responses to this question range from ‘all activities that are related to illicit drugs’ to ‘a set 
of principles or an ideology that conducts public action in this field (e.g. war on drugs, harm 
reduction)’. To prevent both a too large and a too restrictive approach, we will use here a 
definition that has been adapted from Kilpatrick’s (2000) definition of public policies as: ‘A 
system of laws, regulatory measures, courses of action and funding priorities concerning (illicit) 
psychoactive drugs and promulgated by a governmental entity or its representatives.’
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Ireland in figures
Year Ireland EU (27 countries)
Population 2011 4 480 858 502 476 606 (p)
Population by age class 
(% of total population)
15–24
2011
11.7
25–49 38.5
50–64 16.3
GDP per capita in PPS (1) 2010 128 100
Total expenditure on social protection 
(% of GDP) (2)
2009 27.9 29.5 (p)
Unemployment rate (%) (3) 2011 14.4 9.7
Unemployment rate of population 
aged under 25 years (%)
2011 29.4 21.4
Prison population rate 
(per 100 000 of national population) (4)
2010 97.4  
At risk of poverty rate (%) (5) 2010 16.1 16.4
Political system Centralised
(p) Eurostat provisional value.
(1) Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods 
and services produced less the value of any goods or services used in their creation. The volume index 
of GDP per capita in purchasing power standards (PPS) is expressed in relation to the European Union 
(EU-27) average set to equal 100. If the index of a country is higher than 100, that country’s level of GDP 
per head is higher than the EU average and vice versa.
(2) Expenditure on social protection contains: benefits, which consist of transfers in cash or in kind to 
households and individuals to relieve them of the burden of a defined set of risks or needs.
(3) Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed 
persons comprise those aged 15 to 74 who were: (a) without work during the reference week; 
(b) currently available for work; (c) actively seeking work.
(4) Situation in penal institutions on 1 September 2010.
(5) Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, 
which is set at 60 % of the national median equivalised disposable income (after social transfers).
Source: EMCDDA Country overview — Ireland 
(http://www.emcdda.europa.eu/publications/country-overviews/ie)
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Policy timeline — key dates
International and EU developments National developments
1934 Dangerous Drugs Act 1934
UN Single Convention on Narcotic Drugs 1961
1966 Report of the Commission of Inquiry on 
Mental Illness
UN Convention on Psychotropic Substances 1971 Report of the Working Party on Drug Abuse
1973 Ireland joins the European  
Economic Community
1977 Misuse of Drugs Act 1977
1983 Report of Special Government Task Force on 
Drug Abuse
1984 Misuse of Drugs Act 1984
UN Convention Against Illicit Trafficking 
in Narcotic Drugs and Psychotropic 
Substances 
1988
European Plan to Combat Drugs 1990
1991 Government Strategy to Prevent  
Drug Misuse
Report on the European Plan to  
Combat Drugs
1992
EU Plan to Combat Drugs 1995–1999 1995
1996 First report of the Ministerial Task Force on 
Measures to Reduce the Demand for Drugs
1997 Local drugs task forces become operational
UN General Assembly Special Session on 
the World Drug Problem
1998
EU Drugs Strategy 2000–04
EU Action Plan on Drugs 2000–04
2000 National Advisory Committee on Drugs 
established
2001 ‘Building on experience: national drugs 
strategy 2001–2008’ launched
2004 Mid-term review of the national drugs 
strategy
EU Drugs Strategy 2005–12
EU Drugs Action Plan 2005–08
2005 Regional drugs task forces become 
operational
2007 Report of the Working Group on Drugs 
Rehabilitation
EU Drugs Action Plan 2009–12 2009 National Drugs Strategy (interim), 2009–16 
launched
2010 Criminal Justice (Psychoactive Substances) 
Act 2010 becomes law
2012 Steering group report on a national 
substance misuse strategy
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Developing Irish drug control, 1921–1979
Irish drug control legislation was enacted when the country was still part of the 
United Kingdom. The Poisons (Ireland) Act 1870 controlled the sale of a range of 
substances, initially including opium and morphine. The first central drug control 
law following the Anglo Irish Treaty in 1921, when 26 of Ireland’s counties became 
politically independent, while six counties in Northern Ireland remained within 
the United Kingdom, was the Dangerous Drugs Act 1934. It was enacted to fulfil 
Ireland’s obligations under the League of Nations Convention for the Limitation of 
the Manufacture of Narcotics of 1931. The law updated the system for regulating 
the availability of drugs, setting out record-keeping requirements for pharmacists 
and doctors and established unauthorised possession as an offence punishable by 
a fine, imprisonment or both (Working Party on Drug Abuse, 1971). A number of 
complementary regulations were adopted between the mid 1950s and mid 1960s in 
order to scale up drug control and respond to the emergence of new drugs, such as 
amphetamines, barbiturates and tranquilisers, and to the lack of adequate restrictions 
on the availability of medications based on them. 
The Mental Treatment Act 1945 was the first legislation focusing on mental health 
issues, and it made specific reference to ‘addicts’ when setting out provisions for 
voluntary and compulsory admissions to psychiatric hospitals. This reference to 
addiction, stated as being to drugs or intoxicants, however, was primarily concerned 
with alcoholics (Butler, 2002). In 1966, a review of Ireland’s mental health services 
by the recently created Commission of Inquiry on Mental Illness noted that there 
was little drug use and that out of 19 829 patients in mental hospitals in March 
1963, only 16 were in receipt of treatment for drug addiction. On the basis of 
these numbers and the delivery of treatment solely by psychiatrists, the Commission 
advocated the use of a single centralised treatment facility for drug addiction 
(Commission of Inquiry on Mental Illness, 1966). Developments in drug treatment 
occurred some years later, and were based on a model of centralised, abstinence-
orientated, service provision, influenced by British developments. In 1969, the first 
drug treatment facilities were established in Dublin by the Department of Health, 
with an out-patient unit at Jervis Street Hospital, later renamed the National Drug 
Advisory and Treatment Centre, and an in-patient centre at Saint Brendan’s Hospital. 
A voluntary sector treatment body was established in 1973, when the Coolmine 
Therapeutic Community started to treat drug users in Dublin (Butler, 2002).
While remaining at a low level, drug use in Ireland was gradually changing. In 
the early 1950s, the drugs most commonly used were sedatives, tranquilisers and 
barbiturates, with amphetamines being taken in the early 1960s and a shift towards 
10 
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lysergic acid diethylamide (LSD) and cannabis in the late 1960s and 1970s, with 
little use of heroin or other opioids being reported. At that time, a commercial scale 
trade in illicit drugs was not observed (Butler, 2002; Commission of Inquiry on 
Mental Illness, 1966). Supplies of amphetamines, barbiturates and tranquillisers for 
the illicit drugs market were chiefly sourced through thefts from pharmacies, while LSD 
and cannabis were reported to be trafficked only in small amounts (Working Party on 
Drug Abuse, 1971). Garda Síochána (police) statistics for 1969 showed that there 
were 350 known drug users, increasing to 940 by 1970 (Butler, 2002). 
In 1968, drug issues were considered sufficiently important for the establishment 
of a government working party on drug abuse, which was tasked with examining 
Drug control laws in Ireland 
The Misuse of Drugs Acts 1977 and 1984 (MDA) are the main Irish drug laws. There 
are five schedules (lists) of drugs in the legislation, based on the usefulness of the drugs 
and the nature of the controls required. New substances are not ‘added’ to a list, but are 
‘declared’ by government declaration orders to be equivalent to drugs under the MDA. 
Ireland uses a ‘generic’ system, where substances within a defined chemical ‘family’ are 
automatically considered controlled drugs. 
On discovery of drugs, the police have the options of confiscation and informal warning, 
caution, juvenile diversion, arrest referral or prosecution. In the Irish criminal justice 
system, crimes may be tried in a lower or higher court, depending on the seriousness of 
the charge. A summary offence is a minor offence chargeable by way of summons, tried 
before a district court judge, who can usually impose a sentence of no longer than one 
year in prison. Offences considered too serious for the district court follow the indictment 
proceeding and are referred to the circuit criminal courts. Here, the defendant is entitled 
to a trial by jury. In addition to custodial measures, a range of non-custodial options 
are available. The decision may be influenced by a pre-sanction report compiled by the 
Probation Service that includes information on factors that may have contributed to the 
individual’s offending, such as drug addiction. Cases can also be permanently stayed, 
struck out, withdrawn, or taken into consideration (added to a sentence for a different 
offence) (Alcohol and Drug Research Unit, 2008; EMCDDA, 2009).
The MDA distinguishes between possession (for personal use) and possession for sale 
or supply. Possession of cannabis for personal use is punishable by a fine on first or 
second conviction; from a third offence onwards, it may be punished by fines, up to one 
year imprisonment, or both, on summary conviction, and imprisonment for up to three 
years on indictment. Possession of other controlled substances may incur a penalty of 
imprisonment for up to one year, a fine or both, on summary conviction, and up to seven 
years imprisonment on conviction on indictment. Possession of any drug for sale or supply 
attracts penalties of up to one year on summary conviction and up to life imprisonment if 
on indictment. The law states that the court can presume the drugs were for selling based 
on quantity or other relevant matters. A mandatory minimum 10-year sentence is also 
available for supply offences involving more than EUR 13 000 of drugs.
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the extent of drug use and making recommendations to the Minister for Health. Its 
1971 final report placed an equal focus on prevention and treatment, and called 
for the establishment of different offences for personal use and supply, with cannabis 
offences dealt with differently from other drugs. The working party also sought 
the creation of a permanent advisory body, and in 1972 an inter-departmental 
committee on drug abuse was established. Formed on a non-statutory basis, however, 
the committee did not meet regularly, and failed to have an impact on policy (Butler, 
2002). The working party also supported a specialist, centralised system of treatment 
for drug users with a limited referral role for general practitioners. The adoption of 
the Misuse of Drugs Act 1977 (see the box ‘Drug control laws in Ireland’), which 
replaced the 1934 legislation, implemented the differentiation of offences suggested 
in the working party’s final report, and facilitated Ireland’s accession to the 1961 UN 
Single Convention on Narcotic Drugs and the 1971 UN Convention on Psychotropic 
Substances, respectively, in 1980 and 1992 (Butler, 2002). 
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Heroin use and the road towards a new drug policy, 
1980–1995
A marked change in the drug situation occurred in the early 1980s, mainly in the 
capital city of Dublin, with increased heroin use, the emergence of an injecting drug 
culture and commercial scale drug dealing. Crime statistics show an increase from 
501 persons charged with drug offences in 1978 to 1 593 in 1982, and from five 
charged with heroin offences in 1979 to 449 in 1983 (1). Treatment presentations 
at the National Drug Advisory and Treatment Centre increased from 319 in 1979 
to 1 307 in 1982. A Medico-Social Research Board study reported 10 % last year 
prevalence of heroin use among 15- to 24-year-olds in the north inner-city (Butler, 
2002; Dean et al., 1983). In 1985, 27.8 % of 636 individuals tested at the National 
Drug Advisory and Treatment Centre and 22 % of 190 drug users in the largest 
prison tested positive for the human immunodeficiency virus (HIV) (Quigley, 2010). 
Ireland was also facing economic difficulties and political instability, with four 
different ministers for health between 1979 and 1982, and three general elections 
between 1981 and 1982. These circumstances contributed to the slow development 
of a policy response to heroin use, and triggered groups of community activists 
formed in some Dublin inner-city neighbourhoods, for example Concerned Parents 
Against Drugs, to take action against drug dealers. In 1983, responding to the 
changing drug situation and growing community tensions, the Minister for Health 
established the Special Government Task Force on Drug Abuse, comprising six 
ministers of state, to report on drug abuse, with particular reference to Dublin’s 
inner city and focusing on heroin use (Butler, 2002). Following its report, supply 
reduction measures received more attention, including the adoption of the Misuse 
of Drugs (Amendment) Act in 1984. The report also noted that the existing inter-
departmental committee had not effectively monitored the drugs problem, and 
recommended a new structure be developed. In 1985, the Minister for Health 
created the National Coordinating Committee on Drug Abuse to advise government 
and provide the minister with annual reports. Like its predecessor, the Committee 
was established on a non-statutory basis, contributing to infrequent meetings, and 
published only one annual report in 1986 (National Coordinating Committee on 
Drug Abuse, 1986). Thereafter, it had little impact (Butler, 2002) until 1989, when 
it was restructured and developed the first Irish drug strategy (see below).
Significant changes in the organisation and provision of health-related measures 
started in the 1980s, notably the introduction of harm reduction interventions in a low 
(1) The quantities of heroin seized across these years also rose, from 5 g in 1979 to almost 1.3 kg in 1983 
(Butler, 2002).
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profile manner, without any national level strategic policy document (Butler, 2002). In 
1982, the first low-threshold treatment agency in Ireland, the Ana Liffey Drug Project, 
was established in Dublin city, receiving statutory funding from 1985 on (Butler and 
Mayock, 2005). During 1983, the Eastern Health Board (EHB), the regional health 
authority for Dublin, established a network of addiction counsellors, and in 1987 
moved away from services primarily focused on abstinence, making methadone 
maintenance treatment more widely available at the National Drug Advisory and 
Treatment Centre. The EHB implemented additional harm reduction measures in 
1989, establishing an AIDS resource centre, a needle and syringe exchange 
programme, and an outreach service (Butler, 1991). That same year, Merchants 
Quay Ireland, the largest harm reduction orientated drug service operated by the 
voluntary sector, began to receive statutory funding.
Changes continued in the early 1990s, when the EHB moved towards service 
provision in local communities outside of Dublin city, creating small ‘satellite clinics’ 
for drug treatment services, including methadone maintenance. In 1992, the National 
AIDS Strategy Committee delivered its report, supporting methadone maintenance 
for HIV prevention, its use in satellite clinics and the standardisation of prescribing 
practices (National AIDS Strategy Committee, 1992). This triggered the establishment 
of the Expert Group on a Protocol for the Prescribing of Methadone by the Department 
of Health. It called for the creation of treatment identity cards, a central treatment 
list, a registration system for general practitioners and the provision of methadone 
treatment within their practices (Department of Health, 1993; Quigley, 2010). 
The adoption of the Misuse of Drugs (Amendment) Act in 1984 was the main 
legislative development during the 1980s (Butler, 2002). It addressed loopholes in 
the 1979 legislation relating to cannabis cultivation, undertaking drug searches, 
increased sentences for trafficking and removed the requirement for pre-sentencing 
medial and social reports on drug users (Butler, 2002; Flynn and Yeats, 1985; 
O’Mahony, 2008). Ireland also signed the 1988 UN Convention Against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances in December 1989 (2). Precursor 
chemicals used in the manufacture of drugs, such as acetic anhydride (for heroin) 
and ephedrine and pseudoephedrine (for methamphetamine), became subject to 
controls in the 1977 and 1984 Misuse of Drugs Acts and the 1988 Misuse of Drugs 
Regulations (National Coordinating Committee on Drug Abuse, 1991). Further 
legislation and policing efforts were put in place in the mid 1990s. The Criminal 
Justice Act 1994 included provisions for seizing and confiscating assets derived 
from drug trafficking proceeds and, in 1995, the Garda National Drugs Unit was 
established to tackle national and international drug trafficking.
(2) It was ratified in 1996.
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In 1991, drug policy was expressed for the first time in the form of a national drugs 
strategy (National Coordinating Committee on Drug Abuse, 1991). The adoption 
of a top-level policy document mirrored developments in other European countries, 
where drug policies were being set out in this way (Butler, 2002). Treatment, harm 
reduction and outreach received official backing, and it was acknowledged that 
established responses to drug problems, primarily based on supply reduction, 
needed to be balanced with demand reduction measures (National Coordinating 
Committee on Drug Abuse, 1991). The strategy also discussed the use of primary 
care, in conjunction with clinics for methadone maintenance, to extend local 
service provision. The role of environmental factors in drug use was acknowledged, 
specifically, the concentration of heroin problems and injecting drug use in deprived 
inner city areas. The establishment of multi-disciplinary community drug teams in the 
worst-affected areas was provided for, two of which were developed in Dublin during 
1992 (Butler, 2002). However, the strategy lacked an implementation plan, and its 
execution schedule remained therefore vague (National Coordinating Committee on 
Drug Abuse, 1991).
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In the 1990s, several factors led to lasting changes in Irish drug policy. These 
included changes in public policy formulation and expression, a continued sense of 
crisis surrounding HIV/AIDS and injecting drug use and tensions within communities 
affected by drugs. Such tensions became increasingly visible in 1996, when 
community groups such as the Inner City Organisations Network and the Coalition 
of Communities Against Drugs organised anti-drug protest marches. Fourteen 
demonstrations, involving between 500 and 3 000 people, were held between 
August and December 1996 (Quigley, 2010). The murder of Veronica Guerin, a 
prominent crime journalist covering the illicit drugs trade, on 26 June in 1996, added 
to the perception that drug problems were at crisis point (Butler, 2007). 
Available data indicate that Ireland was confronted with serious and often rising 
drug problems. According to a 1997 government discussion paper, ‘Tackling crime’, 
the number of drug offenders doubled between 1990 (2 071) and 1995 (4 021) 
(Department of Justice, 1997). A Garda Síochána (police) study reported that out 
of 19 046 detected indictable crimes (warranting a jury) in the Dublin Metropolitan 
Area during one year, 66 % were committed by drug users (Keogh, 1997). 
Additionally, a 1996 prevalence study provided an estimate of 13 460 opioid users 
aged 15 to 54 in Dublin city, with 40 % being males aged 15 to 24 (Comiskey, 
1998). Five years later, another study calculated 12 456 opioid users in Dublin and 
14 452 in the whole country (Kelly et al., 2003).
External factors played an important role in drug policy changes in Ireland, and 
1996 was a pivotal year in the development of new structural arrangements in this 
area. ‘Delivering better government’ was published that year, and it developed 
the Strategic Management Initiative, an Irish version of New Public Management 
(Department of the Taoiseach, 1996). This triggered changes in the civil service 
in terms of accountability, assigning of responsibility and management of cross-
departmental issues. One example of this is the establishment of the Ministerial Task 
Force on Measures to Reduce the Demand for Drugs in July 1996 (Randall, 2011). 
Their first report, concerning heroin use, marked a shift in policy, its expression 
and delivery (Ministerial Task Force on Measures to Reduce the Demand for Drugs, 
1996), and had a lasting impact on the area. Using epidemiological data, it 
stated the connections between economic deprivation, crime and the use of drugs, 
alongside the links between injecting drug use and the transmission of human 
immunodeficiency and hepatitis C viruses (Butler, 2007; Quigley, 2010). 
The report also called for new drug policy structures such as the Cabinet Drugs 
Committee, designed to provide intra-governmental coordination and bringing 
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together different ministers and the Taoiseach (Prime Minister) to consider policy 
issues. Below it, the Inter-Departmental Group on Drugs, comprised of high-ranking 
civil servants, oversaw policy implementation and acted as a link between local 
and central government. The National Drugs Strategy Team assisted the Inter-
Department Group, while managing the work of the ten local drugs task forces 
(Ministerial Task Force on Measures to Reduce the Demand for Drugs, 1996). The 
latter were implemented in areas with serious heroin problems (Sinclair, 2006), 
and included statutory, voluntary and community sector members (Ministerial Task 
Force on Measures to Reduce the Demand for Drugs, 1996). This mirrored the 
‘social partnership’ approach to policy-making pursued since the adoption of the 
Programme for National Recovery in 1987 (Department of the Taoiseach, 1987). By 
involving those affected within the solutions being applied, the approach reduced 
local dissatisfaction (Quigley, 2010). Ten task forces were originally planned, but 
the number was later increased to fourteen, thirteen of which were located in Dublin 
(Drug Misuse Research Division, 1999).
The new policy coordination structures were set up in 1997, and underwent 
modifications following a change of government. The Cabinet Drugs Committee was 
renamed the Cabinet Committee on Social Inclusion, and a minister of state was 
given responsibility for both the drugs strategy and local development. The overall 
responsibility for coordinating drugs policy was also moved from the Department of 
Heath to the new Department of Tourism, Sport and Recreation. This department was 
regarded as being in a position to provide a neutral handling of the different policy 
spheres covered by the strategy, alongside the fact that it also held responsibility 
for local development and was in charge of coordinating several programmes 
addressing social inclusion (Pike, 2008). 
The Ministerial Task Force’s report also reviewed the organisation of drug treatment 
services, backing methadone maintenance, through expanding the number of general 
practitioners and community pharmacists delivering it, and endorsing the use of a 
low-threshold mobile clinic. The Eastern Health Board’s programme of developing 
local drug treatment clinics, which was facing opposition from communities 
campaigning for services but opposing facilities in their neighbourhoods, also 
received support (Ministerial Task Force on Measures to Reduce the Demand for 
Drugs, 1996). In 1998, the Methadone Treatment Services Review Group supported 
the adoption of a protocol to roll out methadone treatment nationally and the 
Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 
implemented this new methadone prescribing system (Drug Misuse Research Division, 
1999) (see the box ‘The methadone treatment protocol’). This led to significant 
increases in both the numbers of patients and of providers (general practitioners, 
community pharmacies and health board clinics) over the following decade (Quigley, 
2010). Prison based methadone treatment also expanded in 2001, following reports 
19 
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The methadone treatment protocol 
The Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 
1998 set out rules for general practitioners prescribing methadone. Prior to the protocol, 
a limited number of general practitioners prescribed methadone, with those prescribing 
receiving a high volume of patients, and requiring many drug users to travel long 
distances. 
The protocol reduced the potential for overprescribing practices and the diversion of 
methadone to the illicit market. It standardised treatment provision and contributed to 
the development of the capacity of the drug treatment system through use of the primary 
care system, involving general practitioners and community pharmacists. A two-tier 
system of general practitioners was created. Level 1 doctors cannot initiate treatment 
and take a maximum of 15 referred patients from level 2 general practitioners or Health 
Service Executive (HSE) (formerly health boards) drug treatment clinics. Level 2 doctors 
can initiate treatment, receive extensive training from the Irish College of General 
Practitioners and treat 35 patients alone or up to 50 in tandem with another level 2 
doctor (Drug Misuse Research Division, 1999).
The name, address and date of birth of a person receiving treatment, the name of the 
prescribing practitioner and the dispensing pharmacist are notified to the Health Service 
Executive. A drug treatment card, valid for up to one year is issued by an HSE regional 
office for a person receiving treatment. The central treatment list contains details of all 
individuals receiving methadone. Since October 1998, general practitioners cannot issue 
prescriptions for methadone other than to a person issued a drug treatment card. The 
community pharmacy contactor agreement increased treatment delivery in local areas, 
allowing pharmacies to dispense methadone. Pharmacists cannot supply methadone to 
anyone without a drug treatment card, and must forward a record of all prescriptions to 
the Minister for Health. The protocol has been reviewed several times, and is subject to 
ongoing improvements (Drug Misuse Research Division, 1999; Farrell and Barry, 2010; 
Methadone Prescribing Implementation Committee, 2005).
from review groups (Irish Prison Service, 2000, 2001). The same year, a pilot drug 
court commenced operation (see the box ‘The Dublin drug court’). 
Supply reduction legislation was also scaled up, particularly following the murder of 
the journalist Veronica Guerin. In July 1996, the Criminal Justice (Drug Trafficking) 
Act made provision for the detention of a person suspected of committing a 
drug trafficking offence for a maximum of seven days. The Disclosure of Certain 
Information for Taxation and other Purposes Act, launched at the same time, 
facilitated information exchange between the Revenue Commissioners and the Garda 
Síochána. In August, the Proceeds of Crime Act 1996 facilitated the freezing and 
forfeiture of the proceeds of crime. This allowed the recently established Criminal 
Assets Bureau to identify assets acquired through criminal activity and take measures 
to deprive the suspected individuals of them (Drug Research Division, 1997; Quigley, 
20 
Drug policy profiles  •  Ireland
2010). Additional measures were adopted in the Proceeds of Crime (Amendment) 
Act 2005 (Pike, 2008). 
The Criminal Justice Act 1999 added a new section (15A) to the Misuse of Drugs 
Act 1977 to create an offence of possession of drugs valued at EUR 12 700 or 
more, for the purpose of sale or supply (Drug Misuse Research Division, 2000). This 
offence should be punished by a mandatory minimum sentence of ten years in prison. 
Courts were, however, reluctant to apply it because of its impact on the primacy of 
judicial discretion in determining sentences and of a potential for disproportionate 
sentencing. The gap between the legislation and sentencing practices was addressed 
in the Criminal Justice Acts 2006 and 2007. The former introduced a new minimum 
The Dublin drug court
A pilot drugs court was established in Dublin in 2001 under the jurisdiction of the district 
court. It is treatment-orientated, where people with drug problems, charged with non-
violent offences, are referred to treatment programmes rather than sent to prison. 
Irish criminal courts are adversarial, but the drug court judge has a central and active 
role. The prosecution and defence counsel promote public safety while protecting the 
participant’s due process rights. Applicants to the programme should be resident in 
the areas of County Dublin north of the River Liffey or be attending Castle Street drug 
treatment centre in Dublin city. They should be over 17 years of age, be motivated to 
cease drug use, have pleaded guilty or been convicted of certain offences in the district 
court with a likely outcome of imprisonment (Reitox National Focal Point, 2011). 
By 2009, out of the 323 people referred to the court since it started, 22 had successfully 
completed the programme, which has three phases (1). A further 32 remained within it, 
while 143 were ineligible and 109 had had their participation terminated. A review 
of the court was published in 2010 (Department of Justice, Equality and Law Reform, 
2010). It found that only 14 % of participants had successfully completed the programme 
since its establishment, but participation was seen to have had a positive effect on 
offending behaviour, health and personal relationships, even when participants failed 
to complete the programme. The review recommended the programme be extended 
to offenders aged 16–18 years who are before the Children’s Court (Department 
of Justice, Equality and Law Reform, 2010) and suggested measures to improve the 
programme’s effectiveness and success rate (Connolly, 2010). It was decided that the 
drug court should continue for another two years, following the implementation of the 
recommendations (Reitox National Focal Point, 2011). 
(1) Participants move through three phases of the drug court programme: (1) stabilisation and 
orientation; (2) continuation and progression; and (3) reintegration and self-management. A set of 
expectations about the participant’s behaviour and achievements are defined for each phase.
Further information about the drug court can be accessed at: http://www.courts.ie/offices.nsf/
fd1b5d60ef39f31380256e43003d0107/cfaf3511b9b9639e80256e45005861cf?OpenDocument
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ten year sentence for the offence of importing (3) drugs with a value of EUR 13 000 
or more, while the latter facilitated a more effective response to organised crime 
gangs. In 2009, however, the Law Reform Commission noted that the presumptive 
drug offences regime had created a ‘discriminatory system of sentencing where all 
cases are treated alike regardless of differences in the individual cases’ (Connolly, 
2012; Law Reform Commission, 2011). 
An increase in drug policy research occurred from the mid 1990s on, following 
the Strategic Management Initiative. At this time, the Health Research Board’s 
Drug Misuse Research Division (DMRD) (4) undertook epidemiological studies 
and functioned as Ireland’s national focal point to the EMCDDA (5). In 1999, the 
establishment of an (Interim) Advisory Committee on Drugs allowed the level of 
research to be expanded (Drug Misuse Research Division, 2001). Bringing together 
representatives from different sectors, the committee was designed to advise 
government (Quigley, 2010), and was allocated funds of EUR 3.8 million for its 
initial triennial work programme. It funded studies covering the consequences of drug 
use, prevalence, prevention and treatment and rehabilitation (National Advisory 
Committee on Drugs, 2003a) (6).
A new drug strategy ‘Building on experience: national drugs strategy 2001–2008’, 
was adopted in May 2001 (Department of Tourism Sport and Recreation, 2001), 
following a review by the Inter-Departmental Group on Drugs. The new strategy 
increased public involvement in drug policy development, which was evident from the 
inviting of submissions and the hosting of eight regional consultation events, attended 
by 600 people. Ongoing community action was also present during the years after 
the strategy’s launch, with civil society organisations seeking to influence the content 
and direction of drug policy through different means, including holding conferences, 
undertaking research, political lobbying and publishing policy discussion papers 
(Pike, 2008).
The new strategy focused on heroin use, and endorsed the existing structures and 
approach, essentially restating the policy in a way that reflected the Strategic 
Management Initiative’s continuing influence (Drug Misuse Research Division, 2001; 
Quigley, 2010). International developments at the United Nations (1998 UNGASS 
Political declaration and plans of action) and, particularly, the European Union (EU 
drugs strategy 2000–04) also influenced its style and content (Pike, 2008). Built 
(3) Instead of possessing.
(4) Later renamed the Alcohol and Drug Research Unit.
(5) The Health Research Board’s electronic library, including the work of the National Focal Point, can be 
accessed at: http://www.drugsandalcohol.ie/
(6) The National Advisory Committee on Drugs reports can be accessed at: 
http://www.nacd.ie/index.php/publications.html
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on four pillars covering supply reduction, prevention, treatment and research, and 
accompanied by key performance indicators, one hundred actions associated to 
policy actors were set out (Drug Misuse Research Division, 2001; Pike, 2008). A 
focus was placed on increasing access to treatment in communities and prisons and 
reducing the volume and availability of drugs (Department of Tourism Sport and 
Recreation, 2001). Support was also given for the rollout of the drugs task force 
model on a regional level with ten regional drugs task forces being established by 
2005. Their action plans often considered both alcohol and drug issues, reflecting 
the conceptual latitude they were given and the ability to incorporate stakeholders 
from different sectors (Drug Misuse Research Division, 2006; Pike, 2006, 2008). A 
similar process was present in the local drugs task forces’ plans, which had different 
focuses on harm reduction issues depending on the views and opinions of their 
members (Butler, 2007; Quigley, 2010).
In June 2002, following restructuring in the Department of Tourism, Sport and 
Recreation, responsibility for drug policy coordination, including the Drugs Strategy 
Unit, transferred to the new Department of Community, Rural and Gaeltacht Affairs 
(Pike, 2008). In 2004 and 2005, for the first time, a progress review and a mid-
term review of the drugs strategy were undertaken (Department of Community, 
Rural and Gaeltacht Affairs, 2004, 2005). One of the main findings was a need 
for increased efforts in the area of rehabilitation, which became the strategy’s fifth 
pillar (Pike, 2008). This included the establishment of the Working Group on Drugs 
Rehabilitation, which recommended in its 2007 report the development of inter-
agency working protocols and increased detoxification and residential treatment 
places (Department of Community, Rural and Gaeltacht Affairs, 2007; Keane, 
2007) (7). The mid-term review also recommended the range of available treatment 
options needed to expand to address cocaine use (Department of Community, Rural 
and Gaeltacht Affairs, 2005; Pike, 2008). This followed increases in the use and 
trafficking of the drug in Ireland (8). By 2009, trend data from the Health Research 
(7) In 2009, the Health Service Executive established a National Drugs Rehabilitation Implementation 
Committee which later devised a national drugs rehabilitation framework to utilise integrated care 
pathways to provide better rehabilitation services to current and former drug users (Alcohol and Drug 
Research Unit, 2009; Doyle and Ivanovic, 2010; Keane, 2011).
(8) General population surveys conducted in 2002/03 and 2006/07 showed levels of last year prevalence 
of cocaine use among 15- to 34-year-olds at 2 % and 3.1 % respectively, while the number of cocaine 
seizures rose between 1995 and 2007 from 42 to 1 749 cases (Reitox National Focal Point, 2011). 
Increased policy focus on cocaine was reflected in a 2005 Oireachtas (Parliament) report on treatments 
for cocaine use and by the signing two years later of an inter-governmental treaty to participate in 
the Maritime Analysis Operations Centre — Narcotics (MAOC-N), targeting cocaine shipments in the 
Atlantic. The National Advisory Committee on Drugs had conducted two overviews of cocaine use in 
Ireland in 2003 and 2007, while in 2008, a review of crack cocaine use in the Dublin region and a 
strategy to address it was also developed (Connolly et al., 2008; National Advisory Committee on 
Drugs, 2003b; National Advisory Committee on Drugs, 2007).
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Board showed that cocaine had been reported as a main or additional problem 
substance by one-fifth (10 764) of all cases treated for problem substance use 
between 2002 and 2007 (Bellerose et al., 2009).
Twenty drug-related laws were enacted during the timeframe of the new drugs 
strategy. Some of them, such as those aimed at drug trafficking, reflected the 
strategy’s objectives, but others, like those making provision for drug testing, 
represented issues that were not covered in the policy document (Pike, 2008) (9). A 
change was also made to the main drug law in 2006 with the Misuse of Drugs Act 
1977 (Controlled Drugs) (Declaration) Order. It addressed an early phase of the 
so-called ‘legal highs’ phenomenon, following media coverage of the availability 
of ‘magic mushrooms’ in ‘head shops’ and a related death in Dublin (Ryall and 
Butler, 2011). Consequently, psilocin or its esters and any substances, products, 
preparations or other fungi containing them were designated controlled drugs under 
the 1977 Misuse of Drugs Act (Drug Misuse Research Division, 2006). 
(9) International cooperation aimed at disrupting drug trafficking was addressed in the Criminal Justice 
(Illicit Traffic by Sea) Act 2003, the European Arrest Warrant Act 2003, the Garda Síochána (Police 
Co-operation) Act 2003, the Criminal Justice (Joint Investigation Teams) Act 2004 and the Europol 
(Amendment) Act 2006. Public nuisance linked to alcohol or drug intoxication was addressed in the 
Criminal Justice (Public Order) Act 2003, while joint policing committees were provided for under the 
Garda Síochána Act 2005, a broad piece of legislation concerned with the operation of the police force. 
The Criminal Law (Insanity) Act 2006 excluded intoxication from alcohol or drugs from the definition of 
‘mental disorder’ in considering fitness to be tried. The Maritime Safety Act 2005, the Railway Safety Act 
2005, the Safety, Health and Welfare at Work Act 2005 and the Prisons Act 2007 all made provision for 
drug testing in different contexts.
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A new ‘National drugs strategy (interim) 2009–2016’ was launched in September 
2009, and it largely reiterated the approach adopted in 1996 and in 2001. Public 
consultation meetings were hosted during its development phase, and the partnership 
approach to drugs policy, involving collaboration between the statutory, community 
and voluntary sectors was supported in the document. A pillar model was retained 
to provide structure, covering supply reduction, prevention, a combined treatment 
and rehabilitation pillar, research and information, alongside coordination as a 
cross-cutting theme, and 54 actions associated to policy actors were set out in an 
action plan under the different pillars. This was also conceptualised as facilitating a 
fit between the strategy’s measures and those of the EU Drugs Action Plan 2009–12 
(Alcohol and Drug Research Unit, 2009; Connolly et al., 2009; Department of 
Community, Rural and Gaeltacht Affairs, 2009).
The integration of illicit drug and alcohol policies into a new substance misuse 
strategy was considered in the 2009 drug strategy (see the box ‘Alcohol and 
tobacco policies’). Consequently, a steering group delivered a report on this 
approach in February 2012, which envisaged illicit drugs and alcohol being 
addressed in separate documents until after 2016, with both strategies forming 
a new policy approach to substance misuse generally (Department of Health, 
2012a; Pike, 2012) (10). The impact of the steering group’s report and, specifically, 
the implementation of some or all of the recommendations will emerge over time, 
showing how much these policy areas will have moved towards integration. 
A series of drug-related legislative changes took place from 2009 on, with 
developments addressing new psychoactive substances. The new drugs strategy 
requested the Department of Health to review existing laws and to close loopholes 
facilitating the sale of such substances (Department of Community, Rural and 
Gaeltacht Affairs, 2009). Over 200 substances were controlled under the Misuse 
of Drugs Act 1977 (Controlled Drugs) (Declaration) Order 2010. Subsequently, 
the Criminal Justice (Psychoactive Substances) Act was adopted in late 2010, a 
new ‘catch-all’ law, making the sale of any psychoactive substance illegal (see the 
box ‘Criminal Justice (Psychoactive Substances) Act 2010’). The Misuse of Drugs 
(Controlled Drugs) Declaration Order controlled 60 other substances, including 
cathinones and synthetic cannabinoids, in November 2011 (Reitox National Focal 
Point, 2011).
(10) Reflecting the style of the 2009 drug policy, a new alcohol policy was structured around pillars covering 
supply reduction, prevention, treatment and rehabilitation, research and information, and included an 
action plan, defining concrete actions and the policy actors tasked with undertaking them.
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In the area of supply reduction, the strategy called for legislation to be kept under 
continuous review, and this action, alongside ongoing work and other developments 
in the broader drug policy context, gave rise to new laws. The Criminal Justice 
(Amendments) Act 2009 and the Criminal Justice (Surveillance) Act 2009 improved 
existing law’s ability to tackle gang-related crime and violence, and made 
provision for the use of evidence gathered on criminals and terrorists through covert 
surveillance. The Criminal Justice (Miscellaneous Provisions) Act 2009 established 
a gun licensing framework (Pike, 2009a). Offences committed inside and outside 
the state linked to money laundering and the financing of terrorists were targeted, 
in line with an EU Directive, in the Criminal Justice (Money Laundering and Terrorist 
Financing) Act 2010. The Communications (Retention of Data) Act 2011 made 
provision for the providers of fixed and mobile phone and Internet services to disclose 
data when certain offences, such as customs offences, are being investigated. Public 
nuisance related to begging near cash machines was addressed through the Criminal 
Justice (Public Order) Act 2011. The blood alcohol content for drivers was reduced, 
and provision made for impairment tests to establish if a driver is under the influence 
Alcohol and tobacco policies
Since 2011, the Department of Health is responsible for alcohol and illicit drug policies, 
two areas that have developed in separate ways (Butler, 2002). Recent initiatives to 
formulate a substance misuse strategy, covering alcohol and drugs, follow earlier policy 
work on alcohol use by different working groups and committees, such as, the 1996 
national alcohol policy (Department of Health, 1996; Hope and Butler, 2010).
The Intoxicating Liquor Acts 2000, 2003 and 2008 are the central legislation governing 
the control and supply of alcohol (Pike, 2012). The minimum age for the purchase 
of alcohol (beer, wine, spirits) is 18 in off- and on-license premises. National level 
restrictions control the hours and days that alcohol can be sold. Ireland’s per capita 
alcohol consumption for adults over 15 years old in 2009 was 11.3 litres, placing it 
the tenth highest out of 40 OECD countries, the average being 9.1 litres (Department of 
Health, 2012a).
Tobacco control policy has developed as a distinct area, disconnected from alcohol and 
illicit drug policy. A national strategy, ‘Towards a tobacco free society’, was launched in 
2000. The National Tobacco Control Office, part of the Health Service Executive, advises 
the Minister for Health on the implementation of the strategy and legislation (Pike, 2012). 
Adopted under section 47 of the Public Health (Tobacco) Act 2000, the Tobacco Smoking 
(Prohibition) Regulations 2003, introduced a ban on workplace smoking, including 
licensed premises. Ireland was the first country in the world to adopt such legislation 
covering all places of work targeting environmental tobacco smoke (Fong et al., 2006). 
Scoring 69/100, Ireland ranked second out of 30 European countries on the tobacco 
control scale for its combination of tobacco pricing, bans in public places, information 
campaigns, bans on advertising, health warnings on packaging and the provision of 
treatment options for dependent smokers (Joossens and Raw, 2011).
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Criminal Justice (Psychoactive Substances) Act 2010
The Criminal Justice (Psychoactive Substances) Act 2010, entered into force in Ireland 
on 23 August 2010 as a response to a large number of retail outlets, known as ‘head 
shops’, selling new psychoactive substances not controlled under the Irish Misuse of Drugs 
Acts, but the effects of which can be similar to those of cannabis or cocaine. 
The law makes it a criminal offence to advertise, sell or supply, for human consumption, 
psychoactive substances not specifically controlled under existing legislation. These 
are legally defined as substances which have the capacity to stimulate or depress the 
central nervous system, resulting in hallucinations, dependence or significant changes to 
motor function, thinking or behaviour. Medicinal and food products, animal remedies, 
intoxicating liquor and tobacco are excluded.
Under the law, high-level police officers can intervene quickly by serving a ‘prohibition 
notice’ on an offender. If the offender does not comply with it, the courts can issue a 
‘prohibition order’. Selling, advertising and non-compliance with a prohibition order are 
punishable by up to five years in prison. However, no offence or punishment is set out for 
the users of these substances (Reitox National Focal Point, 2010). Following the adoption 
of the new law, the number of head shops fell from more than 113 to 19 during 2010, 
with the remaining outlets no longer selling such substances (Reitox National Focal  
Point, 2011).
of drugs in the Road Traffic Act 2010, which came fully into force in 2011 (Reitox 
National Focal Point, 2011).
The delivery and coverage of established treatment and harm reduction services was 
addressed in the new drugs strategy. A review was sought of the 1998 methadone 
treatment protocol to maximise treatment availability (Department of Community, 
Rural and Gaeltacht Affairs, 2009). The external review commissioned by the Health 
Service Executive recommended altering the protocol to provide for buprenorphine as 
a treatment and the delivery of level 1 methadone treatment to be part of the criteria 
for becoming a general practitioner and the number of level 2 doctors — treatment 
initiators — to be increased alongside the number of patients they can treat, from 
35 to 50 (Farrell and Barry, 2010; Reitox National Focal Point, 2011). A call 
was also made to expand needle and syringe exchange programmes through the 
establishment of services in 65 locations through community pharmacies (Alcohol and 
Drug Research Unit, 2009; Department of Community, Rural and Gaeltacht Affairs, 
2009). 
Mirroring events in the earlier periods of Irish drug policy, a series of changes were 
made to the drug policy coordination structures. Like the impact of the Strategic 
Management Initiative in the mid 1990s, these changes were influenced by a 2008 
review of the Irish public service by the Organisation for Economic Cooperation and 
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Development (Alcohol and Drug Research Unit, 2009; OECD, 2008). The Cabinet 
Committee on Social Inclusion’s remit was adjusted and it was renamed the Cabinet 
Committee on Social Inclusion, Children and Integration. Reflecting the networked 
organisation model set out by the OECD review, the Drugs Strategy Unit and the 
National Drugs Strategy Team were combined into a new structure, the Office of 
the Minister for Drugs, led by the minister of state for drugs policy (Alcohol and 
Drug Research Unit, 2009; OECD, 2008; Pike, 2008). Designed as an integrated 
Drug policy coordination in Ireland
Drug policy is part of the remit of the Cabinet Committee on Social Inclusion, Children 
and Integration, chaired by the Taoiseach (Prime Minister) and comprised of 14 ministers. 
Its function is to provide a strategic and integrated approach to social exclusion issues. 
The minister of state with responsibility for the national drugs strategy and senior civil 
servants from the Oversight Forum on Drugs attend its meetings. 
The Department of Health has overall responsibility for the national drugs strategy. Its 
Drugs Policy Unit manages the implementation of the strategy and is responsible for the 
Oversight Forum on Drugs. The Drugs Programme Unit manages and administers the 
allocation of funds for the Drugs Initiative Programmes undertaken in drugs task force 
areas and manages the work of the Drugs Advisory Group. The head of the Drugs Policy 
Unit acts as National Drug Coordinator at the administrative level, while the minister of 
state with responsibility for the national drugs strategy functions as drug coordinator at the 
political level.
The Oversight Forum on Drugs operates at the inter-departmental level, with 
representatives from all departments, agencies, the community and voluntary sectors 
involved in delivering the national drugs strategy. Meeting four times a year, the Forum 
reviews the implementation of the strategy and proposes solutions to problems, providing 
top-level monitoring of the area. 
The Drugs Advisory Group is tasked with advising the minister of state with responsibility 
for the national drugs strategy on policy and operational issues. Comprised of statutory, 
community and voluntary sector representatives, it supports the work of the drugs task 
forces. 
The National Advisory Committee on Drugs, attached to the Department of Health, is a 
non-statutory body tasked with conducting, commissioning and analysing research and 
advising government on policy developments. 
Fourteen local and ten regional drugs task forces are involved in the creation of strategies 
and service development and delivery at the local level. They include members from the 
statutory, community and voluntary sectors (Alcohol and Drug Research Unit, 2007; Pike, 
2011; Reitox National Focal Point, 2011). In 2012, a review of the task forces and the 
national structures governing them was completed. It recommended that they be renamed 
‘drug and alcohol task forces’, to reflect their role in addressing both drug and alcohol 
problems, and the Drugs Advisory Group be reconstituted as the National Coordinating 
Committee for Drug and Alcohol Task Forces (Department of Health, 2012b). 
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coordination system, the Office was made responsible for overall coordination, policy 
development and management of the drugs task forces (Department of Community, 
Rural and Gaeltacht Affairs, 2009; Pike, 2008). It was supported in its work by the 
Drugs Advisory Group, including members from the community and voluntary sectors, 
to advise on drug strategy operational and policy matters. The new strategy also 
triggered change in the Inter-Departmental Group on Drugs, which was remodelled 
as the Oversight Forum on Drugs and designed to support an integrated approach 
to coordination (Alcohol and Drug Research Unit, 2009; Connolly et al., 2009; 
Department of Community, Rural and Gaeltacht Affairs, 2009; Pike, 2009b).
March 2011 saw further changes to drug policy coordination, following a change 
of government. Drugs policy was transferred back to the Department of Health, 
where it was until the mid 1990s before responsibility for the area was moved to 
other departments that dealt with local and community development (Pike, 2012). 
The Office for the Minister of Drugs was closed, while two new structures, the Drugs 
Policy Unit and the Drugs Programme Unit assumed its functions for drug policy and 
operational issues. Other structures — the Oversight Forum on Drugs, the Drugs 
Advisory Group, the local and regional drugs task forces and the National Advisory 
Committee on Drugs — were retained (Connolly et al., 2012; Reitox National Focal 
Point, 2011) (see the box ‘Drug policy coordination in Ireland’). 
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While there are many differences in how national drug policies have developed 
in Europe, the Irish example provides a timeline that reflects some of the broad 
changes that have taken place in this field. Until the late 1960s, in contrast to the 
comprehensive polices that are common today, national drug policies in Europe were 
often more of a compilation of laws and a few measures, coupled with sporadic 
mental health initiatives. Following an increase in drug-related problems in the late 
1960s and throughout the 1970s, modern policies began to emerge in the form of 
dedicated laws reflecting UN drug conventions and of more specific drug services, 
which were typically abstinence-orientated residential facilities. This first modern 
drug policy model came under strong pressure with escalating heroin problems 
and the spread of HIV among injecting drug users during the 1980s. Consensus 
among policymakers and other stakeholders on the direction of the action taken in 
supply reduction appears to have resulted in the development of specialised police 
forces and new laws to fight organised crime. Drug-demand reduction interventions, 
however, especially the more controversial harm reduction measures, have often 
arisen from initiatives at the local level, only becoming endorsed and institutionalised 
at national level many years later. The achievement of a balance, where supply and 
demand reduction (including harm reduction) have, at least symbolically, similar 
weight, took time to develop and to form the national drug strategies that emerged 
in Europe in the 1990s and 2000s. The public health impetus that drove some of 
these changes in drugs policy will also, nowadays, raise the question of how drug 
and alcohol policies can be better linked. Additionally, the development of the ‘legal 
highs’ phenomenon triggers new legislative developments, which often focus on those 
who sell these substances and not on those who use them.
Ireland’s drug policy has, however, many distinctive features. One of them is the 
drug problem itself, which grew rapidly from the early 1980s on, was mainly located 
in poor areas of the capital city and, at times, linked with violence and public 
demonstrations. This situation contributed to the impetus for government action in 
the drugs sphere, which developed at the local level before being fully endorsed, 
following some delay, in a national policy document. The policy shift that occurred 
in 1996, and was consolidated in 2001, was a combination of many factors, some 
of which were outside the realm of drug policy. These included the adoption of 
the Strategic Management Initiative (i.e. New Public Management) agenda and a 
partnership approach to public policy aimed at increased stakeholder involvement. 
The former gave a new expression to drug policy (clear objectives and the use of 
indicators), while the latter facilitated the involvement of stakeholders with different 
views in implementing the policy. In addition, the influence of drug policy at the EU 
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and UN levels also played a role in shaping the expression of drug policy in national 
strategies (Pike, 2008).
Like many European countries, drug policy coordination has been developed at three 
broad levels in Ireland: the inter-departmental (or inter-ministry), the operational, 
and the regional or local. Several phases of structural change in these mechanisms 
have taken place. At times, this has been linked to changes in government 
and how drug policy’s relationship with other policy areas, such as community 
development and social inclusion, was framed (Pike, 2008). Despite these shifts, 
the underlying approach to working with different sectors and maintaining three 
levels of coordination has remained relatively stable, with structures initially at the 
local and later the regional levels taking on increased importance from the mid 
1990s onwards. The Irish model of drug treatment also evolved in a pragmatic and 
comprehensive way towards the end of the 1990s. This is evident from its expansion 
through the development of prescribing guidelines for methadone maintenance, 
coupled with increased utilisation of the established primary care network — family 
Ireland’s drug situation
The Irish drug situation is characterised by a level of drug use in the general population 
that is often close to the European average. For example, last-year cannabis use among 
young adults (aged 15–34) was 10.3 % in 2010/11, below the current European 
average of 12.4 %. The Irish figure for last-year cocaine use among 15- to 34-year-
olds was 2.8 % in 2010/11, compared to an estimated current average of 2.1 % for 
the European Union and Norway. In terms of trends, general population surveys show 
a stable situation regarding both cannabis and cocaine use among adults in Ireland. 
However, among 15- to 16-year-old school students, the number reporting having ever 
used cannabis decreased from 39 % in 2003 to 18 % in 2011 (EMCDDA, 2012a).
The most recent (2006) estimate of the number of problem opioid users in Ireland had 
a central value of 20 790, which represents 7.2 cases per thousand population aged 
15–64 and is above the estimated European average of 4.2 cases per thousand. The 
latest estimate of the number of drug-induced deaths (overdoses) in Ireland was 203 
cases in 2009, and represents about 65 cases per million population aged 15–64, 
with a European average rate of about 20 cases. The number of newly diagnosed HIV 
cases among drug users (4.9 per million population in 2010) is also above the European 
average (2.54 cases per million), but it has been showing a downward trend in recent 
years.
Every year, Irish law enforcement bodies confiscate large quantities of cannabis products, 
with, in 2010, the quantity of herbal cannabis seized (913 kg) exceeding that of 
cannabis resin (748 kg). Seizures of cocaine and heroin fluctuate from about 5 kg to 
330  kg a year for each of the substances, with the exception of 2007, when almost 
2 tonnes (1 752 kg) of cocaine was seized. 
See EMCDDA (2012b) for further information.
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doctors and community pharmacists — to deliver drug treatment. Importantly, this 
system has been consistently complemented by community and voluntary sector 
service provision, particularly in terms of harm reduction and low-threshold services. 
Today’s Irish drugs policy may be viewed as balanced, with strong supply and 
demand reduction features, expressed in a managerial style that seeks to generate a 
high level of consensus through stakeholder involvement, building on internationally 
established best practices. Changes in the drug situation, which have seen the drug 
problem spread across the country during the 2000s, within a climate of national 
and international economic difficulties have created a context in which this policy 
model and the problems it responds to may undergo further changes. One of them 
may be establishing a national substance misuse strategy, covering illicit drugs and 
alcohol. However, the merits and feasibility of this approach are still being reviewed.
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